<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348149</url>
  </required_header>
  <id_info>
    <org_study_id>PNUKHIRB-2018012</org_study_id>
    <nct_id>NCT04348149</nct_id>
  </id_info>
  <brief_title>Lindera Obtusiloba for Non-small Cell Lung Cancer</brief_title>
  <official_title>Adjunctive Administration of Lindera Obtusiloba on Non-small Cell Lung Cancer Patients Who Receive PD-1 Inhibitors: a Randomized Exploratory Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun-Yong Choi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Institute of Oriental Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korean Medicine Hospital of Pusan National University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, open labelled, non-treatment-controlled study evaluates the safety and
      efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung
      cancer patients who are receiving PD-1 or PD-L1 inhibitors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2018</start_date>
  <completion_date type="Anticipated">December 27, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 27, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>Change from baseline to 6-week and 8-week</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EORTC QLQ-LC13</measure>
    <time_frame>Change from baseline to 6-week and 8-week</time_frame>
    <description>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NK cell percentage in peripheral blood</measure>
    <time_frame>Change from baseline to 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+/CD8+ T cell in peripheral blood</measure>
    <time_frame>Change from baseline to 8-week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total T cell, T-helper cell, T-suppressor cell and B-cell percentage in peripheral blood</measure>
    <time_frame>Change from baseline to 8-week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-list</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lindera obtusiloba extract</intervention_name>
    <description>One package of dietary supplement contains one gram of 70% ethanol extracted powder of Lindera obtusiloba and one gram of glucose powder. Participants intake one package per day for 8 weeks.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged ≥ 20 years

          -  Patients who have understood and signed the informed consent.

          -  Subjects who have been confirmed histologically and radiologically for non small cell
             lung cancer and are scheduled to receive treatment with immune checkpoint inhibitors

          -  Subjects whose urine HCG are negative and who have agreed with the appropriate method
             of contraception in case of women of childbearing potential

          -  Subjects who can fully communicate with their medical doctor about their symptoms or
             quality of life and who can fill out questionnaires

          -  Subjects who can follow up during the clinical trial

          -  Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2

          -  Hemoglobin ≥ 9g/dL

        Exclusion Criteria:

          -  Subjects who are pregnant, breastfeeding, planning to become pregnant or women of
             childbearing potential who do not agree with the appropriate method of contraception

          -  Subjects who have symptomatic and uncontrolled brain or central nervous system
             metastasis

          -  Subjects who complain of uncontrolled pain despite using analgesics

          -  Diastolic Blood Pressure&gt;100mmHg or Systolic Blood Pressure&gt;160mmHg

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels higher than
             2.5 times the upper limit for normal

          -  Creatinine level higher than 1.5 times the upper limit for normal

          -  Subjects who have participated in other clinical trials within 1 months

          -  Subjects with a history of serious drug allergies or who have hypersensitivity to the
             Investigational Product (the main ingredient and its components)

          -  Subjects with autoimmune diseases

          -  Subjects who have alcoholism or drug dependence

          -  Subjects who have cognitive impairment or psychiatric problems

          -  Subjects who have undergone surgery within 2 weeks

          -  Subjects who took other herbal medicine or other medicines within 4 weeks

          -  Subjects who have a medical condition that is likely to affect results or who are
             determined to be inappropriate to participate in this clinical trial at the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-Yong Choi, KMD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korean Medicine Hospital of Pusan National University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Yong Choi, KMD/PHD</last_name>
    <phone>+82-55-360-5953</phone>
    <email>orientdoct@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korean Medicine Hospital, Pusan National University</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-Yong Choi</last_name>
      <email>kmd@pusan.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Korean Medicine Hospital of Pusan National University</investigator_affiliation>
    <investigator_full_name>Jun-Yong Choi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

